REFERENCES

REFERENCES

1. Jack, D., *The challenge of drug discovery*. Drug Design Delivery, **1989.** 4: p. 167-186.

2. Schwartz, H.B., *The Discovery of Modern Medicines*. 1 ed. **1989**: Janssen. Morris Plains, NJ Skyline Publishing. 5-15.

3. Dimasi, J.A., et al., Journal of Health Economics, **1991**. **10**: p. 107-142.

4. Black, J.W., British Journal of Clinical Pharmacology **1986.** 22: p. 52-58.

5. Klimstra, P.D. and A.T. Raphael, *Integrating R & D and business strategy*. Research Technology Management, **1992**. 35: p. 22-26.

6. Roussel, P.A., K.N. Saad, and T.J. Erickson, *Third Generation* **1991**: R & D.Cambridge, MA Harvard Business School Press.

7. Jacques, F.M., L. Linden, and N. Selby, Pharm Executive, **1992**. 12: p. 52-72.

8. Williams D.A.;Lemke ,T.L. Foye's Principle of Medicinal Chemistry **2002:**1-20

9. Seydel, J.K.; Cordes H.P.; Wiese, M.; et al *Quant .Struc. Act. Relat* **1989** .8, 266-278

10. Seydel,J.K. ;AlboresVelasco.M. *Quant .Struc.Act.Relat.* **1992,**11 ,205-210

11. Wrighton S.A.;Ring B.J.*Drug Meta.Rev***1999,**.31,16-25

12. Zevin ,S. Benowitz,N.L *Clin.Pharmacokin.* **1999,**36,430-435

13. Watari,N.; Sugiyama,Y.; et al *J. Pharmacokine. and biopharmaceutics* **1988,**16, 285 -296

14. Wrighton S.A.;Ring B.J.*Toxico.Pathol.***1995**,23,200-205

15. Leo, A.; Hansch, C.;Clurch, C. *J Med Chem*. **1969**, 12,766.

16. McGowan, J.C. Nature **1963**, 200, 1317.

17. Swain, C.G.; Lupton, E.C.; Jr. *J: Am. Chem. Soc.* **1968**, 90: 4328.

18. Hansch, C. *J: Med Chem*. **1968**, 11: 920.

19. Comelis, A.; Lambert, S.;Laszl, A.P. *J. Org. Chem*. **1977**,42: 381.

20. Taft, R. W. Jr. Steric Effects in Organic Chemistry, Ed. Newmann,M.S., John Wiley & Sons, New York, **1956**, pp. 556.

21. Purcell, W.P., Bass, G.E., Clayton, J.M. Strategy of Drug Design - AMolecular Guide to Biological Activity. John Wiley & Sons, New York, **1973.**

22. Hansch, C.; Leo, A.; Unger, S.H.; Kim, K.G.; Nikaitani, D.; Lien, E.J. *J.Med Chem.* **1973**, 16, 1207.

23. Hansch, C.; Rockwell, S.D.; Jow, P. Y.C.; Leo, A.; Steller, E.E. *J Med Chem* **1977**,20,304.

24. Free, S.M., Jr.; Wilson, J.W. *J.Med Chem*. **1964**, 7, 395.

25. Craig, P.N.; Hansch, C. *J.Med Chem.* **1973**, 16, 661.

26. Chang, R.S.L., et al., *Science*, **1985.** 230: p. 177-179.

27. Schreiber, S.L., *Science*, **1991**. 251: p. 283-287.

28. Appelt, A., et al., *Journal of Medicinal Chemistry*, **1991**. 34: p. 1925-1934.

29. Burch, R.M., *J. Receptor Research,* **1991**. 11: p. 101-114.

30. Williams, M. and M.F. Jarvis, Clark, C.R. and Moos, W.H., Biochemical approaches to drug discovery and characterization. Drug Discovery Technologies Edn. 1990, Chichester, UK: Ellis Horwood. 129-166.

31. Williams, M., Medicinal Research Review, **1991**. **11**: p. 147-184.

32. Cuatrecasas, P., Annual Reviews Biochemistry **1974**. **43**: p. 169-204.

33. Marshall, G.R. and C.B. Naylor, *Comprehensive Medicinal Chemistry*. Vol. 4. **1990.** 431-458.

34. Blaney, J.M. and C. Hansch, *Comprehensive Medicinal Chemistry*. Vol. 4. **1990**. 459-496.

35. Snyder, J.P., Medicinal Research Review, **1992**. 11: p. 641-662.

36. Hollenberg, M.D., Receptor triggering and receptor regulation: structure-activity relationships from the receptor's point of view *Journal of Medicinal Chemistry,* **1990.** 33: p. 1275-1281. .

37. Fesik, S.W., NMR studies of molecular complexes as a tool in drug design *Journal of Medicinal Chemistry,* **1991.** 34: p. 2937-2945.

38. Wuthrich, K., et al., Receptor-induced conformation change of the immunosuppressant cyclosporin A. *Science,* **1991**. 254: p. 953-954.

39. Ooms, F., Molecular modeling and computer aided drug design. *Journal of Computer Aided Molecular Design,* **2000**. 7: p. 141-158.

40. Agrawal, A. and E.W. Taylor, 3-D QSAR for intrin sic activity of 5-HT1A receptor ligands by the method of comparative molecular field analysis. *Journal of Computational Chemistry,* **1993**. 14: p. 237 -245.

41. Ferrin, T.E., et al., The MIDAS display system. *Journal of Molecular Graphics*, **1988**. 6: p. 13-27.

42. Vaz, R.J., M. L.R., and J.T. Pelton, *Journal of Computer Aided Molecular Design*, **1998**. 12: p. 99.

43. Tame, J.R.H., *Journal of Computer Aided Molecular Design*, **1999**. 13: p. 99.

44. Green, S.M. and G.R. Maeshall, A Current perspective (3D-QSAR), **1995**. 16: p. 285-291.

45. Martin, Y.C., Quantitative Drug Design. **1978**, New York: Marcel Dekker. 381.

46. Waterbeemed, H.V., Advanced Computer Assisted Techniques in Drug Discovery. 2 ed. **1995,** New York: VCH Publishers Inc. 296.

47. L. B. Kier and L. H. Hall, Quantitative Information Analysis: The New Center of Gravity in Medicinal Chemistry, *Med. Chem. Res.* **1997 ,**7, 335-339

48. L. B. Kier, Molecular Orbital Theory in Drug Research, Academic Press, New York **1971**

49. L. B. Kier and L. H. Hall, Molecular Connectivity in Chemistry and Drug Research, Academic Press, New York **1976**

50. L. B.Kier and L. H. Hall, Molecular Connectivity in Structure-Activity Analysis, John Wiley, New York **1986**

51. .L. B. Kier and L. H. Hall, Molecular Structure Description: The Electrotopological State, Academic Press **1999**

52. Kubinyi, H. 5 ed. Burger's Medicinal Chemistry. **1994**, New York: John Wiley and Sons. 505-530.

53. Stevens, D.G., *Journal of Medicinal Chemistry*, **1991**. **34**: p. 2665-2670.

54. Sneader, W., *Drug Discovery and the Evolution of Modern Medicines*. Vol. 52-62. **1985**, Chichester, U.K.: Wiley.

55. Parnham, M.J. and J. Bruinvels, Discoveries in Pharmacology, **1986**. **1**: p. 36.

56. Martin, Y.C,"Quantitative drug design-A critical introduction"(Marcel Dekker, New York) **1978**

57. Hancsh, C and Fugita, T., *J.Am.Chem.*So c.**1964,** 86,1616

58. Ashutosh Kar, Book Of Medicinal Chemistry, 1-10

59. Crum-Brown , A ; Frazer, T.; Trans. R. Soc. Edinburg **1868**-9, **25**, 151

60. D.V. Daniels, J.R. Gevel, J.R. Jasper, M.S. Kava, J.D. Lesnick, T.D Meloy, G. Stepan, T.J. Williams, D.E. Clarke, D.J. Chang and A.P.D.W. Ford *Eur. J. Pharmacol.* **370 1999** , p. 337.

61. C .Hanch ref 70 pp 47-61 .

62. Nitya Anand, Med Chem Rev **1995** ,559-568

63. Hammet, L.P. *Physical Organic Chemistry*, Mc Graw-Hill, Newyork, **1940**, 131-150.

64. T aft, R.W.; Lewis, I.C. *J. Am. Chem. Soc*. **1959**, 81, 5343

65. Pandya ,S.N; Medicinal chemistry p-1040

66. Hansch, C., Yoshimoto, M., and Doll, M.H., *J.Med Chem.*, 1976,19,1089

67. Hansch, C in "Biological Activity and Chemical Structure "Keverling –Buisman.J.A.Ed.,(Elsevier,Amsterdam) **1977**,P.47

68. Jorgensen,E.C and Reid, J.A.,*J. Med. Chem.*,**1965**,8 ,533

69. Cousse,H., Mouzin,G. and Hinterland, L.D., Eur. J. Med. Chem., **1973**, 4, 466

70. Goodford,P.J., Hudson,A.T., Sheppey,G., Wooton,R., Black,M., Sutherland,G.J. and Wickham,J.C., *J.Med.Chem.*, **1976,**19,1239

71. Cammarata, A. *J. Med Chem.* **1972**, 15: 573.

72. Cammarata, A.;Bustard, T.M**.** *J, Med Chem***. 1974**, 17, 981.

73. Craig, P.N., *J Med Chem*. **1971**, 14,680.

74. Topliss, J.G., Edwards, R.P. *J.Med Chem*. **1979**,22: 1238.

75. Hansch, C.;Leo, A. Substituent constants for correlation analysis in Chemistry and Biology, **1983.**

76. Lein, E.J.; Guo, Z.R.;Li, R.L.; Su, C. T. *J.Pharmaceutical Sci*. **1982**, 71

77. Karelson, M.; Lobanov, V.S. *Chem Rev*. **1996**, 96, 1027-1043.

78. Charton, M. *J. Am. Chem. Soc*. **1975**, 97, 1552.

79. Hansch, C.; Maloney, P.P.; Fujita, T.; Muir, R.M. *Nature*. **1962**,194,178.

80. Fujita, T.; Iwasa, J.; Hansch, C. *J. Am. Chem. Soc.* **1964**, 86, 5175.

81. Hansch, C. *J. Med. Chem*. **1968**, 11, 920.

82. Leo, A.; Hansch, C.; Clurch, C. *J. Med. Chem*. **1969**, 12, 766.

83. Hansch, C.; Leo, A.; Unger, S.H.; Kim, K.G.; Nikaitani, D.; Lein, E.J. *J. Med. Chem*. **1973**, 16, 1207.

84. Nelson-Smith, R.; Hansch, C.; Ames, M.M. *J. Pharm. Sci*. **1975**, 64, 599.

85. Hansch, C.; Rockwell, S.D.; Jow, P.Y.C.; Leo, A.; Steller, E.E. *J. Med. Chem.* **1977**, 20, 304.

86. Free, S.M.; Wilson, J.W. *J. Med. Chem*. **1964**, 7, 395.

87. Cammarata, A.; Bustard, T.M. *J. Med. Chem*. **1974**, 17, 981.

88. Hansch, C., et al., Substituent constants for correlation analysis *Journal of Medicinal Chemistry*, **1977**. 20: p. 304-306.

89. Kubinyi, H., QSAR : Hansch Analysis and Related Approaches. **1993**, New York: VCH Publishers. 57-79.

90. Wolfang, R.J., Development of biologically active compounds by combining 3D QSAR and structure-based design methods. *Journal of Computer Aided Molecular Design*, **2002. 16**: p. 825-830.

91. Hansch, C. and J.M. Blaney, eds. *Drug Design (Fact or Fantasy)*. ed. G. Jolls and K.R.H. Woolridge**. 1984,** Academic Press: New York. 84.

92. Selassie, C.D., *Burger's Medicinal Chemistry and Drug Discovery,*. 6 ed. Vol. 1. **2003**, New York: John Wiley & Sons, Inc. 2-50.

93. R.A., L., et al., *Reviews in Computational Chemistry*. Vol. 17. **2000,** New York: Wiley-VCH. 1.

94. Young, S. and T. Terasaki, *Journal of Pharmacobiological Dynamics* **1990.** 13: p. 353.

95. Saxena, P.N., Archives of International Pharmacodynamics**, 1956.** 126: p. 268

96. Wold, S.; Dunn III, W.J. J. *Chem. Inf. Comput. Sci*. **1983**, 23, 6-13.

97. Hardman,J.G.;Limberd,L.E.The Pharmacological basis of therapeutics,10th Ed,The Mcgraw-HillsCompanies,Inc.**2001**,pp 1381-1384

98. Pandeya,S.N.; Antineoplastic agents in A text book of Organic Medicinal Chemistry ,pp 477- 480

99. Gilman, A., and Philips,F.S.: *Science* 103:409, **1946.**

100. www.cancer.gov

101. Pearson, O.H.: *Cancer* 2:945, **1945.**

102. Karnofsky,D.A .;Cancer,18.1517(1965)

103. Robinowitz,L.J.;Myerson,R.M. Topics in Medicinal Chemistry ,Vol.1 Newyork 1967 pp 80-84

104. Williams,D.A.;Lemke,T.L. Foye's Principles of Medicinal Chemistry 5th ed Lippincott Williams and Wilkins **2002** pp 924- 928-724

105. Larionov, L.F *Cancer Chemotherapy*, Newyork ,Pergamon ,1965

106. Plattner, P.A Ed.,Chemotherapy of Cancer ,Elsevier, Amsterdam,1964

107. www.cancer.org.uk/

108. Dolmans DEJGJ, Fukumura D, Jain RK. Photodynamic therapy for cancer. *Nature Reviews Cance*r **2003**;3(5):380–387.

109. Wilson BC. Photodynamic therapy for cancer: Principles. *Canadian Journal of Gastroenterology* **2002**;16(6):393–396.

110. Vrouenraets MB, Visser GWM, Snow GB, van Dongen GAMS. Basic principles, applications in oncology and improved selectivity of photodynamic therapy. *Anticancer Research* **2003**;23:505–522.

111. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. *Journal of the National Cancer Institute* **1998**;90(12):889–905.

112. Dickson EFG, Goyan RL, Pottier RH. New directions in photodynamic therapy. *Cellular and Molecular Biology* **2003**;48(8):939–954.

113. Capella MAM, Capella LS. A light in multidrug resistance: Photodynamic treatment of multidrug-resistant tumors. *Journal of Biomedical Science* **2003**;10:361–366.

114. J.Soloman, M.J.Alexander and J.l.Steinfeld, *J.Am.Med.Assoc.*, 183,165(1963)

115. S.Farber et al .,Advan.Cancer Res.,4(1956)

116. S.Kofman,T.j.Medrek and R.W.Alexander,Cancer,17,938(1964)

117. M.B. Shimkin and J.BField in Cancer, and Treatment, J.B. Field, Ed., Brown, Boston, 1959 pp-724

118. Duan, D.: *Pharmacology* 601:49-66

119. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. *J Natl Cancer Inst* **1993;**85:1483-91.

120. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effects of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. *N Engl J Med* **1994**;330:1029-35.

121. Omenn GS, Goodman G, Thomquist M, et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. *Cancer Res* **1994**;54(7 Suppl):2038s-43s.

122. Hennekens CH, Buring JE, Manson JE, Stampfer M, Rosner B, Cook NR, et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *N Engl J Med* **1996**;334:1145-9.

123. Lee IM, Cook NR, Manson JE. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: Women's Health Study. *J Natl Cancer Inst* **1999**;91:2102-6.

124. G. Chiosis, A. Rodina and K. Moulick **.**Emerging Hsp90 Inhibitors: From Discovery to Clinic. *Anti-Cancer Agents in Medicinal Chemistry* **2006** vol.6 no. 1 Pp. 1-8

125. E.S. Agoston, M.A. Hatcher, T.W. Kensler and G.H. Posner. Vitamin D Analogs as Anti-Carcinogenic Agents. *Anti-Cancer Agents in Medicinal Chemistry* **2006** vol.6 no. 1 Pp. 53-71

126. I. Kostova. Gold Coordination Complexes as Anticancer Agents. *Anti-Cancer Agents in Medicinal Chemistry* **2006** vol.6 no. 1 Pp. 19-32

127. S.M. Kerwin. Soy Saponins and the Anticancer Effects of Soybeans and Soy-Based Foods *Current Medicinal Chemistry - Anti-Cancer Agents*, Vol. 4, No. 3, **2004** Pp. 263-272

128. Lisa Ann Beltz, Diana Kay Bayer, Amber Lynn Moss, Ira Mitchell Simet.Mechanisms of Cancer Prevention by Green and Black Tea Polyphenols *Anti-Cancer Agents in Medicinal Chemistry* 2006 vol.6,no.5 pp. 389-406

129. Wang, D.; Wiest,O.; Helquist ,P.; Hargest,L.; and Wiech, N.**:**QSAR Studies of PC-3 cell line inhibition activity of TSA and SAHA-like hydroxamic acids**.** *Bioorg. & Med.Chem. Lett.***.** Volume 14, Issue 3. **2004,** Pages 707-711

130. Xie,A .; Liao,C.; Li,Z.; Ning,Z.; Hu,W.; Lu,X .;Shi ,L .;Zhou,J. Quantitative Structure-Activity Relationship Study of Histone Deacetylase Inhibitors. *Curr.Med.Chem. - Anti-Cancer Agents*, Vol. 4, No. 3, **2004** Pp. 273-299

131. Jha,T.; Debnath,B.; Samanta,S. ;Uday A.QSAR Study on Some Substituted Glutamine Analogs as Anticancer Agents *Internet Elec. J. of Molecular Design.*Vol.2,issue no.8, **2003.** p 539-545

132. Verma,R Anti-Cancer Activities of 1,4-Naphthoquinones: A QSAR Study .*Anti-Cancer Agents in Medicinal Chemistry* vol.6, no.5 p . 489-499

133. Fan Y.; Shi LM.; Kohn KW.; Pommier Y.; Weinstein JN. Quantitative Structure-Antitumor Activity Relationships of Camptothecin Analogues: Cluster Analysis and Genetic Algorithm-Based Studies. *J Med Chem* **2001** Vol.;44(20):3254-63

134. French, K. J.; Zhuang, Y.; Schrecengost ,R.S.; Copper, J.E.;, Xia ,Z .; Smith C.D. Cyclohexyl-octahydro-pyrrolo[1,2-a]pyrazine-based inhibitors of human N-myristoyltransferase-1. *J. of Pharm. And Exp. Therapeutics* **2004**

135. Dua,M.; S Revathi,S.; Love Kumar Soni,L.K.; Arun Kumar Gupta A.K.; KaskhedikarS.G QSAR modeling of thalidomide analogs as antiangiogenic and prostate cancer inhibitor using AM1 calculations *Ind.J. of chem* Vol. 46A, **2007**, p . 247-251

136. Debnath,B.;Samanta,S.;Gayen,S.et al QSAR Study on 5-N-Substituted-2-(SubstitutedBenzenesulphonyl) Glutamines as Antitumor Agents throughSynthesis and Biological Evaluation: Part III *Internet Electronic Journal of Molecular Design* **2003** Vol.2

137. Tripathi,G.; Mishra,J.P QSAR studies on pyrrolo(2,1-d)(1,2,3,4) tetrazinones,a new classof azolotertazines.*Ind. Jour. of Chem.***2005** Vol44 pp 1398-1400

138. Slavov,S.; Atanassova,M.; Galabov,B. QSAR Analysis of the Anticancer Activity of 2,5-Disubstituted 9-Aza-Anthrapyrazoles *QSAR & Combinatorial Science* **2006**Volume 26, Issue 2 , Pages 173 – 181

139. Antanasova,M.;Ilieva,S.;Galabov,B. QSAR analysis of 1,4 dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridines with anticancer activit.*Euro.Jour.of Med.Chem* **2007** ,vol 42 pp 1184-1192

140. Prasanna **,S.;** Manivannan,E.; Chaturvedi,S.C. Quantitative structure-activity relationship studies of cyclooxygenase inhibitors: a comprehensive analysis*Drug Development Research* **2005** Vol.64, Issue 4 , Pages 220 – 231

141. Matysiak,J. Evaluation of electronic, lipophilic and membrane affinity effects on antiproliferative activity of 5-substituted-2-(2,4-dihydroxyphenyl)-1,3,4-thiadiazoles against various human cancer cells *Europ. J. of Med. Chem* **2007** Vol.42, Issue 7,Pages 940-947

142. Rahnasto,M.;Raunio,H.;Poso,A.; Wittekindt,C.; Juvonen ,O.R.; **.** Quantitative Structure-Activity Relationship Analysis of Inhibitors of the Nicotine Metabolizing CYP2A6 Enzyme*J. Med. Chem.,* **2005** 48 (2), pp-440 -449,

143. Narsinghani, T.; Chaturvedi, S.C QSAR analysis of meclofenamic acid analogues as selective COX-2 inhibitors *Bio. & Med. Chem. Lett.* **2006** Vol. 16, Issue 2, Pages 461-468

144. Chen,J.C.; Qian,Li.; Shen, Y.; Chen, L.M.; Zheng K.C.QSAR Studies on a Series of 7,8-Dialkyl-1,3-diaminopyrrolo-[3,2-*f*]quinazolines with Anticancer Activity *Chinese Journal of Chemistry* **2006** Vol. 24, Issue 11 , Pages 1531 – 1537

145. Ren,S.; Wang,R.; Komatsu,K.; et al.Synthesis, Biological Evaluation, and Quantitative Structure-Activity Relationship Analysis of New Schiff Bases of Hydroxysemicarbazide as Potential Antitumor Agents *J. Med. Chem.,* **2002** 45 (2), 410 -419,

146. Medina, P.; Casper, R.; Savoured, J. F.; Puirot, M.; *J. Med.Chem.* **2005**, *48, 287*-291.

147. Nebert, D.W.; Roe,A.L.; Dieter,M.Z.; Solis,W.A.; Yang,Y.; *Biochem. Pharmacol.***2000**, *59, 65*-85.

148. Denison, M.S.; Nagy, S.R.; *Annu. Rev. Pharmacol. Toxicol.* **2003**, *43*,309-334.

149. Shimizu, Y.; Nakatsuru, Y.; Ichinose, M.; Takahashi.Y.; Kume, H.; *Proc. Natl. Acad. Sci*. U.S.A., **2000**, *97,* 779-782.

150. Anderson, P.; McGuire, J.; Rubico, C.; Gardin, K.; Whitelaw, M. L.; *Proc. Natl. Acad. Sci. U.S.A.*, **2002**,*99,* 9990-9995.

151. Moennikes, O.; Loeppen, S.; Buchmann, A.; Anderson,P.; Ittrich, C.; *Cancer Res***. 2004**, *64*, 4707-4710.

152. Casper, R. F.; Quesne, M.; Rogers, I. M.; Shirota, T.; Jolivet, A.; *Mol.Pharmacol.* **1999**, *356*, 784-790.

153. Quadri, S.A.; Qadri,A.N.; Hanh,M.E.; Mann,K.K.; Sherr, D.H. ;*Mol. Pharmacol*., **2000**, *58,* 515-525.

154. Savouret, J. F.; Antenos, M.; Quesne,M.; Xu, J.; Milgrom, E.;et al ;*J. Biol. Chem*. **2001**, *276*, 3054-3059.

155. Martin, Y.C.; Drug Design methods: A Critical introduction, Marcel, Dekker, Inc. NewYork, 1987, 315.

156. Hansch, C.; Leo,A .Subsituent constant for correlation Analysis in Chemistry and Biology.Wiley- Interscience :Newyork,1979,P 48.

157. Kiselyov A.S. Semenova.M.; Semenov.V.V.;**2006**, Bioorg. Med. Chem. Lett. 16,1440 (b) Resau, W. 1997, *Nature*, 386, 671.

158. Klagsburun, M.; Moses, M.A. **1999** *Chem.Biol*, 6, R217

159. The anti –angiogenic antibody Avastin^{TM}(Bevacizumab) has recently been approved to treat colorectal cancer, see Culy, C. **2005** *Drugs Today,* 41,23

160. S.L.; Martin, D.F.; Kirkpatrick, P. **2005**, The anti –angiogenic aptamer Macugen ^{TM} (Pegaptanib Sodium) has recently been approved to treat neovascular age-related muscular degeneration; see Fine, *Nat. Rev. Drug Disc* 4,187

161. Jordan, M. A.; Wilson, L. Microtubules as a target for anticancerdrugs. *Nat. ReV. Cancer* **2004**, 4, 253-265.

162. Jiang, J. D.; Wang, Y.; Roboz, J.; Strauchen, J.; Holland, J. F.; Bekesi,J. G. Inhibition of microtubule assembly in tumor cells by 3-bromo-acetylaminobenzoylurea, a new cancericidal compound. *Cancer Res.* **1998**, *5*8, 2126-2133.

163. Dumontet, C.; Sikic, B. I. Mechanisms of action of and resistance to anti-tubulin agents: microtubule dynamics, drug transport and celldeath. *J. Clin. Oncol.* **1999,** *1*7, 1061-1070

164. Young, S. L.; Chaplin, D. J. Combretastatin A4 phosphate: back-ground and current clinical status. *Expert Opin. I*n *Vest. Drugs* **2004**,*13*, 1171-1182.

165. Cushman, M.; Nagarathnam, D.; Gopal, D.; Chakraborti, A. K.; Lin,C. M.; Hamel, E. Synthesis and evaluation of stilbene and dihydro-stilbenederivatives as potential anticancer agents that inhibit tubulinpolymerization. *J. Med. Chem.* **1991**, *3*4, 2579-2588.

166. Cushman, M.; Nagarathnam, D.; Gopal, D.; He, H.-M.; Lin, C. M.;Hamel, E. Synthesis and evaluation of analogues of *(*Z)-1-(4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl) ethene as potential cy-totoxicand antimitotic agents. *J. Med. Chem.* **1992,** *3*5, 2293-2306.

167. **(a)** Nam, N. H. Combretastatin A-4 analogues as antimitotic antitumor agents. *Curr. Med. Chem.* **2003**, *1*0, 1697-1722. **(b)** Hsieh, H. P.;Liou, J. P.; Mahindroo, N. Pharmaceutical design of antimitotic

agents based on combretastatins. *Curr. Pharm. Des.* **2005**, *1*1, 1655-1677.

168. **(a)** Ohsumi, K.; Nakagawa, R.; Fukuda, Y.; Hatanaka, T.; Morinaga,Y.; Nihei, Y.; Ohishi, K.; Suga, Y.; Akiyama, Y.; Tsuji, T. Novelcombretastatin analogues effective against murine solid tumors:design and structure-activity relationships. J. *Me*d. *Che*m. **1998,** *4*1,3022-3032. **(b)** Tron, G. C.; Pagliai, F.; Grosso, E. D.; Genazzani,A. A.; Sorba, G. Synthesis and cytotoxic evaluation of combretafura-zans.*J. Med. Chem.* **2005**, *4*8, 3260-3268. **(c)** LeBlanc, R.; Dickson,J.; Brown, T.; Stewart, M.; Pati, H. N.; VanDerveer, D.; Arman, H.;Harris, J.; Pennington, W.; Holt, H. L.; Lee, M. Synthesis and cytotoxicity of epoxide and pyrazole analogues of the combretastatins. *Bioorg. Med. Chem.* **2005**, *1*3, 6025-6034. **(d)** Perez-Melero, C.;Maya, A. B. S.; Rey, B. D.; Pelaez, R.; Caballero, E.; Medarde M.A new family of quinolone and quinoxaline analogues of combreta-statins.*Bioorg. Med. Chem. Lett.* **2004**, *1*4, 3771-3774. **(e)** Simoni,D.; Romagnoli, R.; Baruchello, R.; Rondanin, R.; Rizzi, M.; Pavani,M. G.; Alloatti, D.; Giannini, G.; Marcellini, M.; Riccioni, T.;Castorina, M.; Guglielmi, M. B.; Bucci, F.; Carminati, P.; Pisano,C. Novel combretastatin analogues endowed with antitumor activity.*J. Med. Chem.* **2006,** *4*9, 3143-3152.

169. Hu, L.; Li, Zhuo-rang.; Li,Y.;Qu,J.etal. Synthesis and structure – Activity Relationship of Carbazole sulphonamide as a Novel Class of Antimitotic Agents Against solid Tumors *J. Med. Chem.* **2006**, *4*9, 6273-6282

170. Pagano, M.A.; Andrzejewska, M.; Ruzzene, M etal. Optimization of Protein Kinase CK2 inhibitors derived from 4,5,6,7-Tetrabromobenzimidazole. *J. Med. Chem.* **2004,** *47*,6239-6247

171. Blume-Jensen, P.;Hunter,T. Oncogenic kinase signaling.*Nature* **2001,***411*,355-65

172. Meggio, F.; Pinna, L.A. One- thousand- and -one substrate of protein kinase CK2. *FASEB J.* **2003,** *17*,348-368

173. Litchfield, D. W. Protein Kinase CK2: Structure, regulation and role in cellular decisions of life and death .*Biochem.J.* **2003**, *369*,1-15

174. Seldin, D.C.; Leder, P. Caesin Kinase IIα transgene-induced murine lymphoma: Relation to Theilleriosis in cattle. *Science* ,**1995**, *267*, 894-897

175. Kelliher, M.A.; Seldin, D.C.; Leder, P. Tal-1 induced cell acute lymphoblastic leukemia accelerated by casein kinase II α .b j _ l ⁄ *J* .**1996,** *15*, 5160-5166

176. Landesman-Bollag, E.; Channavajhala, P. L.; Cardiff, R. D.; Seldin, D. C. p53 deficiency and misexpression of protein kinaseCK2 alpha collaborate in the development of thymic lymphomas in mice. *Oncogene* **199**8, *1*6, 2965-2974

177. Orlandini, M.; Semplici, F.; Ferruzzi, R.; Meggio, F.; Pinna, L.A.; Oliviero, S. Protein kinase CK2α' is induced by serum as a delayed early gene and cooperates with Ha-ras in fibroblast transformation. *J. Biol. Chem.* **199**8, *27*3, 21291-21297.

178. Guo, C.; Yu, S.; Wang, H.; Davis, A. T.; Green, J. E.; Ahmed, K. A potential role of nuclear matrix-associated protein kinase CK2in protection against drug-induced apoptosis in cancer cells. *J.Biol. Chem.* **2001**, *27*6, 5992-5999

179. Folkman, J.*Ann.Surg. 175*, (**1972**), 409-416

180. Kim, K.J.; Li, B.; Winner, J.; Armanini, M.; Gillett, N.; Phillips, H.S.; Ferrara, N. *Nature*, 362, (**1993**) 841-844

181. Leenders, W.P.J. *Int.J.Exp.Pathol*. 79, (**1998**), 339-346

182. Kim, K.J.; Li, B.; Winer, J.; et al *Nature*, 362,(**1993**) ,841-844

183. Kubo, K; Shimizu, T;Ohyama,S *J.Med.chem.48,* **(2005**)1359-1366

184. Hubbard, R.D.; Bamaung N.Y.; Palazzo,F.; Qian Zhang, et al Pyrazolo [3,4-d] pyrimidines as potent inhibitors of the insulin-like growth factor receptor (IGF-IR) *Bioorg.Med.Chem.Lett* ,**2007,** Vol.17, p:5406-5409

185. (a)Yee,D.Br .*J. Cancer* **2006** ,94 ,465; (b) Miller,B.S.;Yee,D.*Cancer Res*.**2005** ,65 ,10123.

186. .Bohula,E.A.;Playford,M.P.;Macaulay,V.M.*Anti-Cancer Drugs* **2003** ,9 ,669.

187. Blum,G.;Gazit,A.;Levitzki,A.*J.Biol.Chem*.**2003** ,278 ,40442.

188. For a recent review of ATP-competitive IGF-IR inhibitors, see :Hubbard,R.D.; Wilsbacher,J.L. *Chem Med Chem*.**2007**, 2, 41.

189. Mitsiades,C.S.;Mitsiades,N.S.;McMullan,C.J.;Poulaki,V.;Shringarpure ,R.;Akiyama,M.;Hideshima,T.;Chauhan,D.;Joseph,M.;Libermann,T.A. ;GarciaEcheverria,C.;Pearson,M.A.;Hofmann,F.;Anderson,K.C.;Kung, A.L.*CancerCell* **2004,** 5 ,221.

190. For a discussion of related pyrazolo [3,4-d] pyrimidines as lck inhibitors,see:Burchat,A.;Borhani,D.W.;Calderwood,D.J.;Hirst,G.C.;L i,B.;Stachlewitz,R.F.*Bioorg.Med.Chem.Lett*.**2006** ,16 ,118,and references cited here in.

191. Cone, R.D. *Nat.Neurosci*. **2005**, 8, 571

192. Jiang,W.; Tucci,F.C.; Tran,J.A.; .Fleck,B.A.; Pyrrolidinones as potent functional antagonists of the humanmelanocortin-4 receptor. *Bioorg.Med.Chem.Lett.*Vol.17,**2007,** p5610-5613

193. .Scarlett, J.M.; Marks, D.L. *Expert Opin.Investig.Drugs* **2005**, 14, 1233.

194. Foster,A.C.;Chen,C.;Markison,S.;Marks,D.L.*I Drugs* **2005** ,8 ,314

195. Amorati,R.; Lucarini,M.; Mugnaini,V.; Pedulli,G.F.;Roberti,M.;Pizzirani,D. *J.Org.Chem* **2004,**69,7101.

196. El-Mowafy, A.M.*Biochem.Biophys.Res.Commun*.**2002**,*291*,1218

197. Estrada-Soto,S.; Lopez-Guerrero,J.J.; Villalobos-Molina,R.; Mata,R *Fitotrapia* **2006,***77,*236

198. Orallo,F.; AlvarCamina,M.; Leiro,J.M.; Gomez,e.; Fernandez,P. *Mol.Pharmacol.* **2002**, *61*, 294

199. Vazquez.G.N.; Diaz,H .M et al Design ,microwave-assisted synthesis, and spasmolytic activity of 2-(alkyloxyaryl)-1*H*-benzimidazole

derivatives as constrained stilbene bioisosteres *Bio.and Med.Chem.Lett* **2006** vol.16,pp 4169-4173

200. Purohit, A.; Woo, L. W. L.; Barrow, D.; Hejaz, H. A. M.; Nicholson,R. I.; Potter, B.V.L.; Reed, M. J. Non-steroidal and steroidalsulfamates: New drugs for cancer therapy. *Mol. Cell. Endocrinol.***200**1, *17*1, 129-135.

201. Reed, M. J.; Purohit, A.; Woo, L. W. L.; Newman, S. P.; Potter, B.V. L. Steroid sulfatase: Molecular biology, regulation, and inhibition. *Endocr. ReV.* **2005**, *2*6, 171-202.

202. Day, J. M.; Newman, S. P.; Comninos, A.; Solomon, C.; Purohit,A.; Leese, M. P.;Potter, B. V. L.; Reed, M. J. The effects of 2-substituted oestrogen sulphamates on the growth of prostate andovarian cancer cells. *J. Steroid Biochem. Mol. Biol.* **2003,** *8*4, 317-325.

203. Raobaikady, B.; Purohit, A.; Chander, S. K.; Woo, L. W. L.; Leese,M. P.; Potter, B. V. L.; Reed, M. J. Inhibition of MCF-7 breast cancer cell proliferation and in vivo steroid sulphatase activity by 2-meth-oxyoestradiol-bis-sulphamate. *J. Steroid Biochem. Mol. Biol.* **2003**,*8*4, 351-358.

204. Raobaikady, B.; Reed, M. J.; Leese, M. P.; Potter, B. V. L.; Purohit,A. Inhibition of MDA-MB-231 cell cycle progression and cell proliferation by C-2-substituted oestradiol mono- and bis-3-O-sulphamates.*Int. J. Cancer* **2005**, 117, 150-159.

205. Suzuki, R. N.; Newman, S. P.; Purohit, A.; Leese, M. P.; Potter, B.V. L.; Reed, M. J. Growth inhibition of multi-drug-resistant breast cancer cells by 2-methoxyoestradiol-bis-sulphamate and 2-ethy-loestradiol-bis-sulphamate. *J. Steroid Biochem. Mol. Biol.* **2003**, *8*4,269-278.

206. Leese, M. P.; Leblond, B.; Smith, A.; Newman, S. P.; Di Fiore, A.;Di Santo, R.; De Simone, G.; Supuran, C. T.; Purohit, A.; Reed, M.J.; Potter, B. V. L. 2-Substituted estradiol bis-sulfamates, multitar-getedantitumor agents: Synthesis, in vitro SAR, protein crystal-lography,and in vivo activity. *J. Med. Chem.* **2006,** *4*9, 7683-7696.

207. Bubert ,C .;Leese, M.P.; Mahon,M.F et al, 3,17-Disubstituted 2-Alkylestra-1,3,5(10)-trien-3-ol Derivatives: Synthesis, In Vitro and In VivoAnticancer Activity *J. Med. Chem* **2007**,*50,* 4431-4443